IRLAB Therapeutics AB announced that dosing has been initiated in a Phase I study of the drug candidate IRL757. IRL757 has been shown in preclinical disease models to counteract apathy - a condition that impairs the quality of life for millions of people with Parkinson's disease and other CNS diseases. Through a development collaboration with MSRD/Otsuka and a grant from The Michael J. Fox Foundation, IRLAB has secured full project funding all the way to clinical Proof-of-Concept.

The Phase I study consists of two parts and aims to document the safety, tolerability, and pharmacokinetic properties of IRL757 in healthy subjects. In the first part, ascending doses of the drug candidate are administered (Single Ascending Dose, SAD), and in the second part, repeated and ascending doses are given (Multiple Ascending Dose, MAD). In addition, the possible influence of concomitant food intake will be documented.

The study is expected to be fully completed in 2024.